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INTRODUCTION
Porcine reproductive and respiratory syndrome virus (PRRSV) is a member of the Arteriviridae family and causes breeding disorders in pregnant sows and respiratory disease in piglets (Albina 1997) . It consists of at least eight structural proteins including six envelope proteins (GP2, E, GP3, GP4, GP5 and ORF5a), a membrane protein and a nucleocapsid (N) protein. PRRSV N protein is the most abundant and immunogenic protein expressed in PRRSV-infected cells (Doan and Dokland 2003) . PRRSV emerged in the USA in 1987 and subsequently spread worldwide, becoming a major pathogen affecting the pig industry (Cho and Dee 2006) . Vaccination is the main strategy for control of PRRS; however, current vaccines are not adequately effective, especially for the control of heterologous PRRSV strains. Vaccine failure sometimes occurs because of high variation in the PRRSV genome and the ability of PRRSV to subvert the host immune system (Vu, Pattnaik and Osorio 2017) . Therapeutic agents against PRRSV therefore need to be developed to supplement this control strategy. Indeed, several types of antiviral agents, such as Hypericum perforatum extract (Pu et al. 2009 ), tilmicosin (Lin et al. 2016 ) and artificial microRNAs (Xiao et al. 2011) , have been tested for antiviral effects against PRRSV infection. Doxycycline (Dox) is a second-generation tetracycline with anti-inflammatory activity and a broad spectrum of antimicrobial activity (Bonnetblanc 2002) . Accumulating evidence suggests that Dox possesses broad activity against viral infection, in addition to its antimicrobial and anti-inflammatory activities. For example, Dox inhibited the replication of murine retrovirus (Sturtz 1998) , flavivirus (Yang et al. 2007; Topno et al. 2016 ) and vesicular stomatitis virus (VSV; Wu et al. 2015) in vitro. Furthermore, Dox combined with the antiviral drug ribavirin effectively alleviated chikungunya virus (CHIKV) infection in mouse models (Rothan et al. 2015) . The current study evaluated the antiviral effect of Dox against PRRSV, and showed that Dox effectively restrained PRRSV infection in vitro.
MATERIALS AND METHODS

Agents, virus and cells
Dox at a concentration of 1 mg/ml was prepared, as described previously (Wu et al. 2015) . The highly pathogenic PRRSV strain (SH-PRRS01) was cultured and titered in Marc-145 cells generated from African green monkey kidney cells and permissive to PRRSV replication (Kim et al. 1993) . Marc-145 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (Thermo Fisher Scientific, Carlsbad, CA, USA) containing 10% fetal bovine serum (FBS) (Thermo Fisher Scientific).
Quantitative real-time reverse transcription polymerase chain reaction
RNA isolation and quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) were carried out, as described previously (Wang et al. 2016) . Total RNAs were isolated from PRRSV-infected cells using TRIzol reagent (Thermo Fisher Scientific). The mRNA levels of PRRSV N protein were determined using the primers 5 -ATCATCGCTCAACAAAACCA-3 and 5 -GACACAATTGCCGCTCACTA-3 . GAPDH (glyceraldehyde-3-phosphate dehydrogenase) gene was used as an internal control (primers: 5 -AGAAGGCTGGGGCTCATTTG-3 and 5 -AGGGGCCATCCACAGTCTTC-3 ). PRRSV replication was determined by normalizing the PRRSV N protein mRNA levels to those of GAPDH.
Analysis of PRRSV replication
Marc-145 cells infected with PRRSV at a multiplicity of infection (MOI) of 0.1 were harvested with supernatants and freezethawed three times. PRRSV replication was titered by 50% tissue culture infective dose (TCID 50 ) assay (Xu et al. 2012) , or by qRT-PCR. To detect PRRSV replication by immunofluorescence assay, Marc-145 cells infected with PRRSV were collected at 36 h postinfection (hpi) and subjected to immunofluorescence assay with antibody specific to PRRSV N protein (SDOW-17, Rural Technologies, Brookings, SD, USA) (Wang et al. 2012) .
Cytotoxicity assay
Cytotoxicity assay was carried out, as described previously (Wu et al. 2015) . Briefly, 5 × 10 3 Marc-145 cells per well were grown on a 96-well plate at 37
• C for 24 h and subsequently incubated in culture medium containing Dox at concentrations of 0.01-8.0 μg/ml for 36 h. Cell viability was measured using the WST-1 cell proliferation reagent (Roche Applied Science, Penzberg, Germany). The 50% cytotoxic concentration (CC 50 ) value was calculated using GraphPad Prism 6.0 (GraphPad Software, La Jolla, CA, USA).
Antiviral analysis
Marc-145 cells grown on a 24-well plate were rinsed three times with phosphate-buffered saline (PBS) and inoculated with 0.1 MOI PRRSV at 37
• C for 1.5 h. The cells were then rinsed three times with PBS and subsequently incubated in DMEM containing 2% FBS and Dox at concentrations of 0.02-1.0 μg/ml, or at the indicated concentration. PRRSV replication was measured by TCID 50 assay or qRT-PCR at 36 hpi. The 50% effective concentration (EC 50 ) was calculated using GraphPad Prism 6.0. Dox at a concentration of 0.5 μg/ml was added to Marc-145 cells before and during PRRSV infection to determine the viral replication stage affected by Dox.
Analysis of viral adsorption and entry
We analyzed the effect of Dox on viral adsorption to host cells. Marc-145 cells were grown on a 24-well plate, washed three times with PBS pre-cooled at 4
• C and inoculated immediately with 0.1 MOI PRRSV in combination with Dox at concentrations of 0.05-0.5 μg/ml. After 1.5 h incubation at 4
• C, the cells were rinsed three times with pre-cooled PBS to remove unattached virus particles and immediately harvested for qRT-PCR analysis. The PRRSV particles attached to Marc-145 cells were quantified using qRT-PCR. We analyzed the effect of Dox on PRRSV entry into host cells by inoculating Marc-145 cells with 0.1 MOI PRRSV at 4
• C for 1.5 h, followed by three washings with pre-cooled PBS to remove unattached virus particles. The cells were then incubated with culture medium containing Dox at concentrations of 0.05-0.5 μg/ml at 37
• C for 1.5 h. After three washings with PBS, the cells were cultured in DMEM containing 2% FBS at 37
• C for 36 h, and the replication of PRRSV that entered the cells was quantified using qRT-PCR.
Immunofluorescence assay
Marc-145 cells infected with 0.1 MOI PRRSV were mock-treated or treated with Dox at a concentration of 0.5 μg/ml. The cells were harvested at 36 hpi for analysis of the expression of PRRSV N protein by immunofluorescence assay with an anti-PRRSV N protein monoclonal antibody (Rural Technologies, Brookings, SD, USA). The immunofluorescence assay was performed as described previously (Zhu et al. 2013) .
Statistical analysis
Student's t-test or two-way analysis of variance (ANOVA) were used for significance analysis.
RESULTS
Dox reduces the cytopathic effect of PRRSV infection
Dox cytotoxicity was determined by incubating Marc-145 cells with Dox at different concentrations (0.01-8.0 μg/ml). Dox at concentrations <1.0 μg/ml showed no significant cytotoxicity in Marc-145 cells (Fig. 1A) , and the CC 50 was approximately 1.93 ± 0.18 μg/ml (Fig. 1B) . We then analyzed the effect of Dox on the cytopathic effect (CPE) of PRRSV infection. PRRSV-infected Marc-145 cells were treated with Dox at concentrations of 0.02-1.0 μg/ml, and the CPE of PRRSV infection was visualized under microscope. PRRSV infection induced a severe CPE characterized by cell shrinkage and clumping (Song et al. 2012) in the absence of Dox treatment (0 μg/ml), compared with mockinfected cells (Fig. 1C) . Dox treatment reduced the CPE in PRRSVinfected cells in a dose-dependent manner. These observations indicated that Dox treatment reduced the PRRSV-induced CPE.
Dox restrains PRRSV replication in cultured cells
Given that Dox reduced the PRRSV-induced CPE, we determined if Dox inhibited PRRSV replication in Marc-145 cells. PRRSVinfected cells were treated with Dox at concentrations of 0.02-1.0 μg/ml, and PRRSV titers were determined using the TCID 50 assay. PRRSV titers were significantly reduced in cells treated with Dox at concentrations of 0.2-1.0 μg/ml, compared with mock-treated cells ( Fig. 2A) , suggesting that Dox inhibited PRRSV replication. These results were further confirmed using qRT-PCR. PRRSV mRNA levels were significantly decreased in cells treated with Dox, in a dose-dependent manner (Fig. 2B) . The EC 50 of Dox was approximately 0.25 ± 0.05 μg/ml (Fig. 2C ). We also detected the expression of PRRSV N protein in mock-and Doxtreated cells by immunofluorescence assay. The fluorescence intensity of PRRSV N protein was obviously lower in Dox-treated cells (+Dox) compared with mock-treated cells (−Dox), as indicated by green fluorescence (Fig. 2D) . The growth curves of PRRSV in mock-and Dox-treated cells differed significantly (P < 0.0001, two-way ANOVA) (Fig. 2E ). These observations indicated that Dox restrained PRRSV replication in Marc-145 cells.
Dox influences the early stage of PRRSV replication
We analyzed the stage at which Dox influenced PRRSV infection. Marc-145 cells were incubated with Dox for the indicated periods during PRRSV infection (Fig. 3A) , and PRRSV replication was detected using qRT-PCR. PRRSV mRNA levels in cells treated with Dox (+Dox) before PRRSV inoculation (2, 5 and 10 h preinfection) were similar to those in mock-treated cells (−Dox) ( Fig. 3B) , suggesting that pre-treatment of cells with Dox had no significant effect on PRRSV replication. However, PRRSV mRNA levels in cells treated with Dox at the early stage (1, 2 and 5 hpi) of PRRSV infection were significantly decreased compared with levels in mock-treated cells, while Dox treatment at 10 and 16 hpi had no significant effect on PRRSV replication. These observations revealed that Dox influenced the early stage of PRRSV replication.
Dox enhances PRRSV adsorption to Marc-145 cells
Although Dox influenced the early stage of PRRSV replication, the level of PRRSV mRNA in cells treated with Dox during PRRSV inoculation (Ad 0 h) was notably higher than the level in mock-treated cells (−Dox) (Fig. 3B) . To confirm this result, we inoculated Marc-145 cells with PRRSV in combination with 0.5 μg/ml Dox, followed by incubation at 37
• C for time periods of 15-120 min. PRRSV mRNA levels in mock-(−Dox) and Doxtreated (+Dox) cells were determined using qRT-PCR. Dox treatment significantly increased PRRSV mRNA levels compared with mock-treatment (Fig. 4A) , suggesting that Dox promoted PRRSV adsorption to and/or entry into host cells. The viral adsorption and entry steps can be separated experimentally by incubating virus at 4 • C for adsorption and then raising the temperature to 37
• C for entry (Bengali, Townsley and Moss 2009 ).
We therefore determined if Dox assisted viral adsorption by inoculating Marc-145 cells with PRRSV in combination with Dox at 4
• C for 1.5 h, and then harvesting the cells to quantify the presence of PRRSV particles attached to cells by qRT-PCR. Dox treatment (+Dox) significantly increased the levels of PRRSV mRNA in a dose-dependent manner, compared with mock treatment (−Dox) (Fig. 4B) , suggesting that Dox enhanced PRRSV adsorption to host cells. We determined if viral entry was also assisted by Dox treatment by inoculating Marc-145 cells with PRRSV at 4
• C for adsorption, followed by incubation at 37
• C for entry in the presence of Dox. Replication of PRRSV that entered the Marc-145 cells was quantified using qRT-PCR. PRRSV mRNA levels were similar in Dox-and mock-treated cells (Fig. 4C ), indicating that Dox had no effect on PRRSV entry into host cells. Taken together, these data indicated that Dox treatment promoted PRRSV adsorption to host cells, but had no effect on PRRSV entry into host cells.
DISCUSSION
The current study aimed to analyze the antiviral activity of Dox against PRRSV, which is responsible for huge economic losses in the pig industry (Cho and Dee 2006) . We showed that Dox reduced the PRRSV-induced CPE and effectively restrained PRRSV replication in cultured cells. Dox is a wellknown antibiotic with a broad spectrum of antimicrobial activity (Bonnetblanc 2002) . The antiviral effect of Dox was primarily described in 1998 (Sturtz 1998) and has since been reinforced in several followed-up studies (Yang et al. 2007; Wu et al. 2015; Topno et al. 2016) . However, the antiviral activity of Dox is still poorly studied, and its antiviral spectrum remains unclear. To date, Dox has shown antiviral activity against the replication of murine retrovirus (Sturtz 1998) , dengue virus (DNV) (Yang et al. 2007) , Japanese encephalitis virus (Topno et al. 2016) , VSV (Wu et al. 2015) and CHIKV (Rothan et al. 2015) in vitro. Our data thus not only revealed the antiviral effect of Dox against PRRSV but also broadened its antiviral spectrum. Dox possesses antimicrobial and anti-inflammatory activities (Bonnetblanc 2002) . Its antimicrobial activity is based mainly on its ability to interact with the bacterial ribosome and impair protein synthesis (Griffin, Ceballos and Villarreal 2011) , while its anti-inflammatory activity is achieved partially by modulating the expression of a variety of pro-inflammatory cytokines including interleukins 6 and 8, and tumor necrosis factor-α (Leite et al. 2011; Di Caprio et al. 2015) . However, the mechanism underlying the antiviral activity of Dox is poorly understood. Dox interfered with the adsorption and entry of DNV and CHIKV, probably by interaction with viral envelope proteins involved in viral adsorption and entry into host cells (Yang et al. 2007; Rothan et al. 2014; Rothan et al. 2015) . However, Dox had no effect on VSV adsorption and entry (Wu et al. 2015 ). In the current study, Dox enhanced PRRSV adsorption but had no effect on viral entry. These previous observations, together with our data, suggested that Dox might play different roles in the steps of viral adsorption and entry. Dox was previously shown to inhibit the post-infection replication of DNV, VSV and CHIKV (Rothan et al. 2014; Rothan et al. 2015; Wu et al. 2015) . We also observed that Dox restrained the early stage of PRRSV replication after viral entry into host cells. Overall, these observations reveal that Dox influenced viral replication at the post-infection stage, though the mechanism whereby Dox achieves this effect is unknown. Dox has been shown to penetrate into target cells and bind extensively to proteins (Aronson 1980; Cunha, Sibley and Ristuccia 1982) . A previous study (Wu et al. 2015) , as well as the current results, demonstrated that pre-treatment of cells with Dox had no significant effect on viral replication, suggesting that Dox might inhibit viral replication by targeting viral proteins necessary for viral infection. Indeed, Dox was shown to inhibit the activity of DNV NS2B-NS3 serine protease in an in vitro protease assay (Rothan et al. 2014) , and to bind to CHIKV cysteine protease according to computational studies (Rothan et al. 2015) ; both these proteases are involved in the cleavage of viral polyproteins during viral infection.
Although vaccination is the main strategy for the control of PRRSV, the occurrence of vaccine failure indicates the additional need for therapeutic agents against PRRSV infection. We showed that Dox significantly inhibited PRRSV replication in cultured cells, suggesting its potential clinical application for the treatment of PRRSV infection. However, a previous study indicated that Dox alone resulted in a limited reduction in CHIKV load in the blood of CHIKV-infected mice, while Dox combined with the antiviral drug ribavirin alleviated CHIKV infection in animal models (Rothan et al. 2015) . Similar results were observed in influenza patients treated with Dox, in those cases Dox administered with the antiviral drug oseltamivir provided effective treatment (Quispe-Laime et al. 2010 ). These observations suggest that the synergistic effect of Dox combined with other antiviral drugs should be considered when evaluating the potential clinical applications of Dox for viral infections.
